{
    "root": "2faf514b-295b-cba8-e063-6394a90a04b3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ondansetron",
    "value": "20250306",
    "ingredients": [
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SACCHARIN SODIUM",
            "code": "SB8ZUX40TY",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32112"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "SODIUM CITRATE, UNSPECIFIED FORM",
            "code": "1Q73Q2JULR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53258"
        },
        {
            "name": "ONDANSETRON HYDROCHLORIDE",
            "code": "NMH84OZK2B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7774"
        }
    ],
    "indications": {
        "text": "ondansetron oral solution indicated prevention nausea vomiting associated : highly emetogenic cancer chemotherapy , including cisplatin greater equal 50 mg/m 2 initial repeat courses moderately emetogenic cancer chemotherapy radiotherapy patients receiving either total body irradiation , single high-dose fraction abdomen , daily fractions abdomen ondansetron oral solution also indicated prevention postoperative nausea and/or vomiting .",
        "doid_entities": [
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "full prescribing information recommended adults pediatrics . ( 2 ) patients severe hepatic impairment : exceed total daily dose 8 mg. ( 2.2 , 8.6 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "ondansetron oral solution , usp clear , colorless light yellow liquid characteristic strawberry odor , contains 5 mg ondansetron hydrochloride dihydrate equivalent 4 mg ondansetron per 5 ml : 5 ml unit dose cups : 30 cups ( 3 x 10 ) ndc 60687-252-86 store 20\u00ba 25\u00bac ( 68\u00ba 77\u00baf ) ; excursions permitted between15\u00ba 30\u00ba c ( 59\u00ba 86\u00baf ) [ usp controlled room temperature ] . protect light . seal broken .",
    "adverseReactions": "ondansetron contraindicated patients : known hypersensitivity ( e.g . , anaphylaxis ) ondansetron components formulation [ ( 6.2 ) ] . receiving concomitant apomorphine due risk profound hypotension loss consciousness .",
    "indications_original": "Ondansetron oral solution is indicated for the prevention of nausea and vomiting associated with:\n                  \n                     highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m\n   2\n                     \n                     initial and repeat courses of moderately emetogenic cancer chemotherapy\n                     radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen\n                  \n                  Ondansetron oral solution is also indicated for the prevention of postoperative nausea and/or vomiting.",
    "contraindications_original": "See full prescribing information for the recommended dosage in adults and pediatrics. (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg. (2.2 , 8.6)",
    "warningsAndPrecautions_original": "Ondansetron oral solution, USP a clear, colorless to light yellow liquid with a characteristic strawberry odor, contains 5 mg of ondansetron hydrochloride dihydrate equivalent to 4 mg of ondansetron per 5 mL:\n   \n\t5 mL unit dose cups: 30 cups (3 x 10) NDC 60687-252-86\n  \n                  \n                  Store at 20\u00ba to 25\u00baC (68\u00ba to 77\u00baF); excursions permitted between15\u00ba to 30\u00ba C (59\u00ba to 86\u00baF) [see USP Controlled Room Temperature]. Protect from light.\n                  \n                     DO NOT USE IF SEAL IS BROKEN.",
    "adverseReactions_original": "Ondansetron is contraindicated in patients:\n                  \n                     known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any of the components of the formulation \n   [see \n    Adverse Reactions (6.2)]. \n   \n                     \n                     receiving concomitant apomorphine due to the risk of profound hypotension and loss of consciousness.",
    "drug": [
        {
            "name": "Ondansetron",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7773"
        }
    ]
}